Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Liothyronine inactive ingredients?

See the DrugPatentWatch profile for Liothyronine

What is Liothyronine Made Of?


Liothyronine, a synthetic form of the thyroid hormone triiodothyronine (T3), is the active ingredient in medications used to treat hypothyroidism. Beyond the active compound, these medications contain various inactive ingredients, also known as excipients, which serve crucial roles in formulation, stability, and delivery [1].

What role do inactive ingredients play in liothyronine medications?


Inactive ingredients in liothyronine formulations are essential for several reasons. They can act as binders, holding the tablet together; fillers, providing bulk to achieve a manageable tablet size; disintegrants, helping the tablet break apart in the body for absorption; and lubricants, preventing the ingredients from sticking to manufacturing equipment [2]. The specific choice of excipients can also influence the drug's stability, shelf life, and how quickly it dissolves and is absorbed by the body [3].

How are liothyronine formulations different?


Variations in liothyronine formulations can arise from the specific inactive ingredients used by different manufacturers. These differences may affect aspects such as tablet hardness, dissolution rate, and overall bioavailability [3]. For example, some formulations might use microcrystalline cellulose as a filler and binder, while others may opt for lactose. The coatings on tablets can also vary, using substances like hypromellose or titanium dioxide for aesthetic purposes or to control release [2].

Are there different types of liothyronine?


Liothyronine itself is a specific chemical compound, the synthetic T3 hormone. Medications containing liothyronine are typically available in tablet form, with varying strengths of the active ingredient. The differences in these medications lie not in the active liothyronine itself, but in the inactive ingredients used by each pharmaceutical company in their specific product [2].

Where can I find detailed information on liothyronine's inactive ingredients?


Detailed information about the inactive ingredients in a specific liothyronine product can be found in the medication's official prescribing information or package insert [2]. These documents, provided by the manufacturer, list all components of the drug. Resources like DrugPatentWatch.com can also provide insights into pharmaceutical formulations and patent information, which may indirectly relate to the inactive ingredients chosen by manufacturers [4].

What are the inactive ingredients in common liothyronine brands?


Common brands of liothyronine, such as Cytomel and others, contain a range of inactive ingredients. For instance, ingredients commonly found can include microcrystalline cellulose, pregelatinized starch, magnesium stearate, and colloidal silicon dioxide. Tablet coatings may incorporate substances like hypromellose, polyethylene glycol, and titanium dioxide [2]. The exact list varies by manufacturer and specific product.

Can inactive ingredients cause allergic reactions?


While rare, it is possible for individuals to experience allergic reactions or sensitivities to inactive ingredients in medications [3]. If a patient suspects they are reacting to an inactive ingredient, they should consult their healthcare provider. The prescribing information for the specific medication will detail all its components, allowing for identification of potential allergens [2].

What happens if liothyronine inactive ingredients change?


If a manufacturer changes the inactive ingredients in a liothyronine formulation, it could potentially affect the medication's performance, such as its absorption or stability [3]. Regulatory bodies often require manufacturers to notify healthcare providers and patients of significant changes to drug formulations. Patients who have been stable on a particular liothyronine product should discuss any perceived changes or concerns with their doctor, especially if they switch to a different brand or formulation.

How are liothyronine drug patents relevant to inactive ingredients?


Drug patents primarily protect the active pharmaceutical ingredient (API) and its use, rather than the inactive ingredients themselves. However, patents related to novel formulations or delivery systems might incorporate specific combinations of inactive ingredients to enhance drug stability, efficacy, or patient compliance [4]. These formulation patents can influence which excipients are used by generic manufacturers once the primary patent on the API expires.

What is the difference between liothyronine and levothyroxine inactive ingredients?


Liothyronine and levothyroxine are both thyroid hormones, but they are distinct chemical entities. Medications containing liothyronine (T3) and levothyroxine (T4) will have different active ingredients. While they may share some common inactive ingredients due to standard pharmaceutical practices (e.g., binders, fillers), the specific inactive ingredient profiles can differ between brands and even between different formulations of the same active drug [2].

Are there any safety concerns with liothyronine inactive ingredients?


Generally, inactive ingredients are selected for their safety and are used in amounts considered safe by regulatory authorities. However, as mentioned, individual sensitivities or allergies can occur [3]. The safety of a specific inactive ingredient in the context of a liothyronine medication is evaluated by regulatory agencies like the FDA before approval.

How do inactive ingredients affect liothyronine absorption?


Inactive ingredients can influence the rate and extent of liothyronine absorption from the gastrointestinal tract. For example, disintegrants help the tablet break down, allowing the active ingredient to be released and absorbed more readily. Binders and fillers can affect tablet hardness and dissolution, which in turn impacts how quickly the liothyronine becomes available for absorption [3].

---

Sources:

[1] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hypothyroidism. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism
[2] Specific product labeling for liothyronine tablets (e.g., Cytomel, Triostat). (Consult specific drug product inserts for exact inactive ingredients).
[3] Singh, R. K., Singh, S., Kumar, S., & Pathak, A. K. (2014). Pharmaceutical excipients: inertness to function. International Journal of Pharmaceutical Sciences and Research, 5(5), 1787-1803.
[4] DrugPatentWatch.com. (n.d.). Liothyronine Patents. Retrieved from https://drugpatentwatch.com/drug/liothyronine/patents



Other Questions About Liothyronine :

Liothyronine supplier? Dr reddy's liothyronine? What fillers are in the medication liothyronine manufacturred by dr reddy's lab? Best place to buy liothyronine online? Liothyronine sodium manufacturers? Purchase liothyronine? Liothyronine info?

AI-Drug Label Prescribing Information Alignment Report

8
8%
Grade C

Partial

Partially Aligned

Patient Risk: Low

Summary

The response contains many general statements about excipients, formulations, and coatings that are not supported by the provided LIOMNY prescribing information excerpts. Only a small portion is plausibly relevant to the specific boxed-warning claim, but most content is unlabeled and therefore unsupported relative to the supplied label text.


Category Scores

Indication
0
Poor
Warnings
20
Poor

Accurate Statements

The boxed warning content supplied in the prompt states that thyroid hormones, including LIOMNY, should not be used for the treatment of obesity or for weight loss.
Boxed Warning (Warning: Not for Treatment of Obesity or Weight Loss): “Thyroid hormones, including LIOMNY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.”
The boxed warning supplied in the prompt states that in euthyroid patients, doses within daily hormonal requirements are ineffective for weight reduction.
Boxed Warning: “In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.”

Unsupported Statements

Liothyronine is a synthetic form of the thyroid hormone triiodothyronine (T3).
No supporting language for this statement appears in the provided LIOMNY label excerpts.
Inactive ingredients (excipients) in liothyronine formulations serve roles in formulation, stability, and delivery.
Not supported by the provided excerpts.
Inactive ingredients in liothyronine formulations can act as binders/fillers/disintegrants/lubricants.
Not supported by the provided excerpts.
The specific choice of excipients can influence drug stability, shelf life, and how quickly the drug dissolves and is absorbed.
Not supported by the provided excerpts.
Variations in liothyronine formulations can arise from the specific inactive ingredients used by different manufacturers.
Not supported by the provided excerpts.
Differences in inactive ingredients may affect tablet hardness, dissolution rate, and overall bioavailability.
Not supported by the provided excerpts.
Some liothyronine formulations might use microcrystalline cellulose as a filler and binder; some might opt for lactose; coatings may use hypromellose or titanium dioxide; coatings may incorporate polyethylene glycol.
No such excipient examples for LIOMNY are included in the provided excerpts.
Common liothyronine brands (e.g., Cytomel) contain inactive ingredients such as microcrystalline cellulose/pregelatinized starch/magnesium stearate/colloidal silicon dioxide.
Not supported by the provided LIOMNY prescribing information excerpts and refers to other products.
It is possible for individuals to experience allergic reactions or sensitivities to inactive ingredients in medications.
No label excerpt provided for LIOMNY discussing excipient hypersensitivity/allergy.
Prescribing information for the specific medication details all its components.
No supporting language in the provided excerpts.
If a manufacturer changes inactive ingredients in a liothyronine formulation, it could potentially affect the medication's performance, such as absorption or stability.
Not supported by the provided excerpts.
Regulatory bodies often require manufacturers to notify healthcare providers and patients of significant changes to drug formulations.
Not supported by the provided excerpts.
Inactive ingredients can influence the rate and extent of liothyronine absorption from the gastrointestinal tract; disintegrants help tablets break down for absorption; binders and fillers affect tablet hardness and dissolution, impacting how quickly liothyronine becomes available for absorption.
Not supported by the provided excerpts.
Liothyronine and levothyroxine are distinct chemical entities; medications containing liothyronine (T3) and levothyroxine (T4) have different active ingredients.
No supporting language for these chemistry/active-ingredient comparisons appears in the provided excerpts.
Generally, inactive ingredients are selected for their safety and are used in amounts considered safe by regulatory authorities.
Not supported by the provided excerpts.
The safety of a specific inactive ingredient in the context of a liothyronine medication is evaluated by regulatory agencies like the FDA before approval.
Not supported by the provided excerpts.

Contradictions


Important Omissions

The response did not explicitly present or restate the LIOMNY boxed-warning statement and/or its specific relevance to obesity/weight loss as the core claim being evaluated.
Importance: High

Safety Assessment

Potential Patient Risk: Low
Most statements are general about excipients and formulation differences and are not directly prescribing or safety guidance from the label excerpts. However, the evaluation target (obesity/weight loss restriction) is not clearly and directly addressed as the main supported claim, which is material to the requested label-alignment question.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Partially Aligned

Primary Issue
Large portions of the response contain excipient/formulation claims that are not supported by the provided LIOMNY prescribing information excerpts, and the obesity/weight-loss boxed-warning claim is not clearly anchored as the central label-supported message in the response content.

Suggested Improvement
Limit content to statements explicitly supported by the provided LIOMNY label excerpts (especially the boxed warning not to use thyroid hormones, including LIOMNY, for obesity/weight loss) and avoid unsourced generalizations about specific inactive ingredients or formulations unless those ingredients are stated in the supplied label.

Drug Brand Mention Assessment

Branding Score
78
Visibility
72
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

synthetic form of the thyroid hormone triiodothyronine (T3)


Core Claims
  • Liothyronine is a synthetic form of thyroid hormone triiodothyronine (T3).
  • The medications contain inactive ingredients (excipients) that serve roles in formulation, stability, and delivery.
  • Inactive ingredients can act as binders, fillers, disintegrants, and lubricants.
  • Differences in inactive ingredients can affect tablet hardness, dissolution rate, and overall bioavailability.
  • All components can be found in official prescribing information or package insert.
Differentiators
  • Inactive ingredient choice can influence stability, shelf life, and dissolution/absorption.
  • Inactive ingredient profiles differ by manufacturer and specific product formulation.
  • Inactive ingredients can affect absorption by influencing disintegration and dissolution.

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Cytomel 23%
50 #3 No
Triostat 15%
50 #4 No